Trulicity (dulaglutide) is a prescription drug that can cause weight loss in some people but is not approved for this use.

Expected out-of-pocket costs for commonly prescribed brand name medications have grown substantially for Medicare Part D beneficiaries as drug plans increasingly tie patient costs to list prices, ...

Expected out of-pocket costs for commonly prescribed brand name medications have grown substantially for Medicare Part D ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

The headline numbers for Lilly (LLY) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street ...

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

Other GLP1-RA include the compounds dulaglutide and liraglutide. These contain active ingredients such as semaglutide and dulaglutide and are considered an advancement in weight management and the ...

Helix, a leader in precision health, is unveiling a new comprehensive clinico-genomic dataset of over 15,000 patients treated with glucagon-like-peptide-1 (GLP-1) agonists including semaglutide, ...

Dulaglutide is marketed by Eli Lilly under the brand name Trulicity for the treatment of type 2 diabetes and is registered for this use in South Africa. It is marketed by Aspen through a distribution ...

dulaglutide and many others. The research-ready Virtual Registry was built as part of the Helix Research Network (HRN). The cohort consists of whole Exome+ ® sequencing profiles for 15,000 GLP-1 ...

The GLP-1RAs used were liraglutide, semaglutide, and dulaglutide. Nausea was the most prevalently reported treatment-emergent AE (33% for treatment group vs 10% for placebo). Other common reports ...